Neutralizing antibodies (NAbs) have significant preventive and therapeutic effects. They mainly target the RBD region and can block the binding site of COVID-19 to the ACE2 receptor. COVID-19 NAbs are a low contamination risk and highly specific, which play a crucial role in the research of COVID-19 treatments. Meanwhile,
The nucleocapsid (N) is a major structural protein of SARS-CoV-2. It is highly conservative, providing an ideal marker for immunodiagnosis. Fapon self-developed monoclonal antibodies have high sensitivity, specificity, and batch-to-batch consistency, with no cross-reactivity with other pathogens (human coronaviruses, flu, pneumonia, etc.). Different application scenarios are supported with stable bulk
Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain from HEK293 cells. The antigens can be used for total antibodies detection to SARS-CoV-2 virus in double-antigen sandwich immunoassay. Our antigens are manufactured to the highest quality standards and are performance guaranteed for the applications listed on the detailed datasheets.
Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain from HEK293 cells. The antigens can be used for total antibodies detection to SARS-CoV-2 virus in double-antigen sandwich immunoassay. Our antigens are manufactured to the highest quality standards and are performance guaranteed for the applications listed on the detailed datasheets.